Nalfurafine hydrochloride to treat pruritus: a review

Abstract: Uremic pruritus has a great negative influence on quality of life in hemodialysis (HD) patients and, importantly, negatively affects mortality risk. Recently, nalfurafine hydrochloride, an opioid κ-selective agonist, has been officially approved for resistant pruritus in HD patients on the basis of a well-evidenced clinical trial in Japan. From clinical observation, it has been suggested that the upper neuron system plays a role in its pathogenesis. According to previous experimental results, using mice injected with opioids, dynorphin suppresses itch through binding κ-opioid receptors, suggesting that κ-opioid opioid receptor agonists act as potential therapeutic reagents for pruritus in HD patients. In Japan, a large-scale placebo-controlled study was performed to examine the efficacy and safety of oral nalfurafine hydrochloride for intractable pruritus in 337 HD patients. Two daily doses of 2.5 or 5 µg nalfurafine or placebo were orally administered for 2 weeks, and clinical responses were analyzed. The results showed that the mean decrease in the visual analog scale for pruritus from baseline was 22 mm in the 5 µg nalfurafine hydrochloride group (n=114) and 23 mm in the 2.5 µg group (n=112). These reductions were statistically significant compared with 13 mm, which is the mean decrease of visual analog scale in the placebo group (n=111), demonstrating that nalfurafine is an effective and safe drug for uremic pruritus in HD patients. Moreover, another open-label trial (n=145) examining the long-term effect of 5 µg oral nalfurafine revealed the maintenance of the antipruritic effect of nalfurafine for 52 weeks. In addition, on the basis of recent data showing κ-opioid receptor expression in the epidermis of atopic dermatitis and psoriasis, nalfurafine hydrochloride also can be potentially used for these two skin diseases.

Keywords: nalfurafine hydrochloride, uremic pruritus, opioid κ-selective agonist, hemodialysis

Introduction

The hemodialysis (HD) patient population in Japan has been growing every year, and a Japanese nationwide statistical survey of 4,238 dialysis facilities indicated that the number of new dialysis patients was 38,055 in 2012, and the number of dialysis patients per million was 2,431.2. Although HD negatively affects the quality of life (QOL) of the patients, uremic pruritus in particular has a great negative influence on their QOL. The Dialysis Outcomes and Practice Patterns Study (1996–2004) collected the previous data from 18,801 HD patients and showed that moderate to extreme pruritus was experienced by 42% of the patients. Further, pruritus was associated with feeling drained, poor sleep quality and QOL, depression, and importantly, a higher mortality risk.

Similar results were obtained in a Japanese report assessing 1,773 HD patients. Therefore, treatment for pruritus in HD patients was very important for
not only their QOL but also their prognosis. Unfortunately, pruritus is often resistant to treatment with various conventional drugs. Indeed, various treatments such as gabapentin, capsaicin cream, ultraviolet B therapy, thalidomide, endocannabinoid cream, and tacrolimus ointment were used in clinical practice, and in some cases, these options were found to be effective. However, there were no drugs satisfactorily effective for severe HD-related pruritus. As for the clinical studies, even if preferential results for some drugs were reported once, they were followed by studies with contradictory results. Collectively, uremic pruritus is still a very difficult target to treat, and new effective treatments are expected to be developed.

Recently, nalfurafine hydrochloride has been officially approved for resistant pruritus in HD patients on the basis of a well-evidenced clinical trial in Japan. In this review, uremic pruritus in HD patients, its pathophysiology, and this new drug are reviewed. In addition, potentials of nalfurafine hydrochloride as a therapeutic reagent for other pruritic skin diseases are discussed.

### HD-induced pruritus and its pathophysiology

Cutaneous manifestations in HD patients are divided into two groups: specific and nonspecific abnormalities. The former includes pruritus, xerosis, hyperpigmentation or hypopigmentation, and acquired ichthyosis. Nonspecific abnormalities include acquired perforating disease (Figure 1), calciphylaxis, bullous dermatosis, and fibrosing dermopathy of uremia. Among these complications, most conditions are associated with pruritus. Pruritus also occurs in patients with end-stage renal disease and is referred to as uremic pruritus or chronic kidney disease-associated pruritus. This symptom lasts for months to years in most cases and is resistant to conventional treatments. As mentioned earlier, pruritus has great influence on the patients’ QOL and prognosis.

One reason for the difficulty in the development of effective therapeutic reagents for uremic pruritus is that its pathophysiology is still not fully uncovered. Until now, various substances have been investigated as possible pathogenic factors in pruritus associated with chronic renal disease. For example, according to previous case reports, persistent uremic pruritus of patients with secondary hyperparathyroidism decreased after parathyroidectomy, therefore, parathormone was speculated to be a potential pruritogen. Nevertheless, intradermal application of parathormone did not cause a significant skin reaction in humans, and further, this hormone could not be detected in uremic pruritus patients, indicating that the likelihood of parathormone as a pruritogen is low. In addition, further clinical study and the development of parathormone-related reagents were not carried out.

On the basis of elevated plasma histamine in patients with uremic pruritus, histamine has been suggested to be a pathogenic substance. However, antihistamines could not suppress pruritus in HD patients, and therefore histamine is unlikely to be a pruritogen. In addition, tryptase, another mediator released from mast cells in the serum of patients with uremic pruritus, was elevated, suggesting mast cells play some role in its pathogenesis.

From the clinical finding that xerosis is often seen in HD patients, pathogenesis of HD-induced pruritus can be ascribed to skin barrier dysfunction. Xerosis is associated with systemic diseases such as renal failure, HD, cholestatic jaundice, and liver cirrhosis. Pruritus caused by these systemic diseases is resistant to antihistamines, possibly because skin barrier destruction induces an increase of neuron fibers in the epidermis. Indeed, neuron-specific enolase-immunoreactive nerve fibers were reported to increase in the epidermis of HD patients. However, moisturizers or emollients, which exert their therapeutic activity through the improvement of skin barrier function, are generally ineffective for HD-related pruritus, suggesting the upper neuron system plays a role in the condition’s pathogenesis.

On the basis of previous results of experiments using mice injected with opioids, itching is induced by opioids through central µ-opioid receptors. In contrast, dynorphin suppresses itch through binding κ-opioid receptors. From these findings, the balance between µ- and κ-opioid opioid
receptors can regulate pruritus, suggesting κ-opioid opioid receptor agonists as a potential therapeutic reagent for pruritus in HD patients.

**Nalfurafine hydrochloride as a new antipruritic drug**

A highly κ-selective agonist U-50488H was constructed in 1982 after long-term efforts toward the development of opioid κ-selective agonist without morphine-like adverse effects such as respiratory depression, constipation, and physical dependence. However, because U-50488H and its derivatives caused different adverse effects such as dysphoria and psychotomimetic effects, unfortunately, they could not reach clinical use. Later, a Japanese group succeeded in designing and developing nalfurafine hydrochloride (TRK-820) (Figure 2), a new type of nonpeptide κ-agonist with a novel chemical structure, in 1998. This reagent has the tyrosine-glycine moiety for endogenous opioid peptides such as dynorphins. This structure was constructed on the basis of the "message-address concept." According to this notion, the 4,5-epoxymorphinan skeleton is defined as the message subsiding acting as opioids, and the other structural part is defined as the address subsiding regulating the receptor type selectivity. Nalfurafine hydrochloride is a potent and selective agonist for mouse, rat, guinea pig, and human κ-opioid receptors without significant activity on µ- and δ-opioid receptors. This drug shows little or no suppressive effect on the secretion of potential mediators for pruritus, including histamine; cytokines such as tumor necrosis factor α, interleukin 1β, and interleukin 6; and prostaglandins such as prostaglandin E₂ or D₂. In addition, the affinities of nalfurafine hydrochloride to various kinds of receptors were examined by binding assays, and it was found that nalfurafine hydrochloride bound to the muscarinic acetylcholine M₁ receptor with very low affinity (Ki = 1,700 nmol/L) but did not displace radioligands from a variety of other binding sites. On the basis of animal experiments using pruritogen-induced scratching in mice, nalfurafine hydrochloride suppressed scratching behaviors, and this inhibitory effect was antagonized by intracerebroventricular (central) administration of norbinaltorphimine, a κ-opioid receptor antagonist in mice, demonstrating the antipruritic effect of nalfurafine hydrochloride through central κ-opioid receptor activation. From the results of conditioned place preference procedure experiments using rats, nalfurafine at 10–40 µg/kg did not produce either place aversion or preference, suggesting an absence of drug aversion and addiction. Further, nalfurafine would constitute a new, effective, and safe reagent, so that a clinical study was undertaken.

**Clinical trials of nalfurafine hydrochloride for HD-induced pruritus**

According to a meta-analysis of two randomized placebo-controlled studies, it was revealed that intravenous nalfurafine three times a week significantly reduced pruritus in 144 HD patients. In this meta-analysis, the worst itching, itching intensity, and sleep disturbances were significantly decreased in the nalfurafine group compared with in the placebo group, demonstrating for the first time the antipruritic activity of nalfurafine hydrochloride in humans.

In Japan, a large-scale placebo-controlled study was performed to examine the efficacy and safety of oral nalfurafine hydrochloride for intractable pruritus in 337 HD patients. All enrolled patients suffered from an itch resistant to antihistamines for 2 weeks, or drugs approved for the treatment of pruritus or moisturizing agents during a 1-year period before the clinical trial. Two doses of daily 2.5 or 5 µg nalfurafine or placebo were orally administered for 2 weeks, and clinical responses were analyzed. The results showed that the mean decrease in the visual analog scale (VAS) for pruritus from baseline was 22 mm in the 5 µg nalfurafine hydrochloride group (n=114) and 23 mm in the 2.5 µg group (n=112). These reductions were statistically significant compared with 13 mm, which is the mean decrease of VAS in the placebo group (n=111). When 50% or more reduction of VAS values was estimated as a significant response, 32.5% (37/114) patients in the 5 µg nalfurafine group and 28.6% (32/112) in the 2.5 µg nalfurafine group showed a significant response. In contrast, 17.1% (19/111) patients in the placebo group showed a significant response. The significant response

![Figure 2 Chemical structure of nalfurafine hydrochloride.](image-url)
rate was significantly higher in the 2.5 and 5 µg nalfurafine groups than the placebo.

On the basis of these data, oral nalfurafine hydrochloride (2.5 or 5 µg/day) is effective for uremic pruritus resistant to conventional treatments in HD patients. Moreover, the same Japanese group designed another open-label trial to examine a long-term effect of 5 µg oral nalfurafine for 52 weeks. Although 211 HD patients with a treatment-resistant pruritus were enrolled, 145 completed the study. In the pretreatment period, the mean pruritus VAS was 75.2 mm, significantly decreasing to 50.9 mm at week 2, 33.6 mm at week 24, and 31 mm at week 52, suggesting the prolonged efficiency on pruritus. However, at 4 weeks after the treatment cessation, the VAS significantly increased to 47.9 mm.

In this study, nighttime pruritus was monitored by the Shiratori severity score (patient assessment). The mean decrease of this score was 0.97, 1.55, and 1.57 at week 2, 24 and 52, respectively, indicating maintenance of the antipruritic effect of nalfurafine until week 52. In this long-term trial, adverse drug reactions occurred in 103 (48.8%) patients, and 6.2% discontinued the treatment as a result of adverse drug reactions. The adverse reactions were as follows: insomnia (15.2%), constipation (3.3%), blood prolactin elevation (0.9%), somnolence (1.9%), dizziness (0.9%), pruritus (0.9%), diarrhea (0.9%), malaise (0.9%), mood alteration (0.9%), eczema (0.5%), vomiting (0.5%), anemia (0.9%), and blood thyroid-stimulating hormone elevation (0.5%). There were no clinically significant alterations in the vital signs or electrocardiograph findings. In addition, the addiction liability was assessed, but none showed psychological dependence on nalfurafine. Likewise, there was no evidence for physical dependence. In this line, another international multicenter study examined the possibility of abuse liability of nalfurafine in 146 HD patients. In this clinical trial, 5 µg nalfurafine was administered intravenously for up to 52 weeks. The questionnaires of the Addiction Research Centre Inventory and modified Short Opiate Withdrawal Scale were administered to the 146 HD patients and 81 end-stage renal disease patients without pruritus as controls. Then, there was no significant difference between the two groups in the Addiction Research Centre Inventory and modified Short Opiate Withdrawal Scale, indicating no evidence of abuse liability. Because uremic pruritus is reportedly a risk factor for depression in HD patients, we examined the effect of oral nalfurafine hydrochloride on pruritus and anxiety in HD patients. Then we found that nalfurafine hydrochloride significantly reduced the VAS for pruritus and state-trait anxiety inventory (STAI1) (state anxiety), but not STAI2 (trait anxiety), suggesting the efficacy of nalfurafine hydrochloride on not only pruritus but also mental condition in HD patients. Trait anxiety is characterized by a longer history, and therefore can be expected to show resistance to the treatment for only 4 weeks. Furthermore, as no psychiatric drugs were administered to the patients, and nalfurafine itself has no antianxiety effect, the effect of nalfurafine on anxiety is likely to be through itch relief. This notion is supported by previous reports showing that pruritus correlates with anxiety in connection with other skin diseases such as atopic dermatitis, psoriasis, and skin burn. Means of STAI1 and two scores of healthy volunteers older than 45 years (n=805) were 35.5±8.920 and 37.74±10.03, respectively. A comparison of the scores of our patients before treatment with the scores of these controls shows that both STAI1 and STAI2 were significantly higher in the patients, thus demonstrating both high state and high trait anxiety in our HD patients.

Pharmacokinetics

As for pharmacokinetics, after a single administration of 2.5 µg of nalfurafine hydrochloride to HD patients, $T_{max}$ was 4.25 hours, $C_{max}$ 3.15 pg/mL, and $t_{1/2}$ 14.21 hours. In the case of administration with 5 µg/day of nalfurafine, $T_{max}$ was 3 hours, $C_{max}$ 6.51 pg/mL, and $t_{1/2}$ 14.03 hours. Furthermore, after repeated administration of 2.5 µg/day for 12 days, $T_{max}$ was 4.14 hours, $C_{max}$ 5.70 pg/mL, and $t_{1/2}$ 25.33 hours. When 5 µg/day nalfurafine was administered in the same manner, $T_{max}$ was 3.86 hours, $C_{max}$ 10.25 pg/mL, and $t_{1/2}$ 28.34 hours. From these findings, $C_{max}$ area under the curve, and $t_{1/2}$ increase more after repeated administration than after a single administration. The decyclopropylmethylation of nalfurafine is catalyzed by CYP3A4, CYP2C8, and CYP2C19, with CYP3A4 functioning as the major metabolic enzyme. Eventually, this reagent and its metabolites are eliminated through the dialysis membrane used for HD. The plasma level of this drug was below the detection limitation 1 week after the study completion, indicating there was no systemic accumulation of nalfurafine. Collectively, nalfurafine is effective for HD-related pruritus and safe in terms of addiction and abuse liability.

Potential of nalfurafine hydrochloride for the treatment of other skin diseases

As mentioned earlier, µ- and κ-opioid receptors are key players in regulating pruritus in the central nervous system, but epidermal keratinocytes reportedly express these opioid receptors both in vitro and in vivo, suggesting nalfurafine can exert its antipruritic activity through κ-opioid receptors.
in the epidermis. This possibility is significant because many skin diseases with pruritus involve epidermal changes, such as spongiosis, hyperkeratosis, and acanthosis. The prototype of such cutaneous diseases is atopic dermatitis, which causes severe itch and, subsequently, scratching, exacerbating inflammation. For treatment for atopic dermatitis, it is very important to suppress itch to prevent such exacerbation. In clinical practice, antihistamines are widely used for this purpose, but in some cases, they are not effective enough to control pruritus. Therefore, a new potential antipruritic drug is expected. Along these lines, the expression of only \( \kappa \)-opioid receptors, not \( \mu \)-opioid receptors, was downregulated in the epidermis of atopic dermatitis patients compared with in normal healthy controls.\(^{53}\) In addition, after the improvement of dermatitis by psoralen-ultraviolet A therapy, the expression of \( \kappa \)-opioid receptors was restored in the epidermis. From these findings, the intraepidermal \( \kappa \)-opioid system plays a pivotal role in controlling peripheral itch in atopic dermatitis. Moreover, according to an animal experiment using Japanese mice (Traf3ip2/Act \( \mu \)-deficient mice), nalfurafine suppresses scratching behavior in the mice.\(^{54}\) Collectively, nalfurafine may be a very hopeful drug for pruritus in atopic dermatitis.

Classically, psoriasis was defined as a nonpruritic skin disease, but recently, accumulating evidence has revealed that a high percentage of psoriasis patients also suffer from pruritus, and subsequently, their QOL is greatly affected by itch.\(^{55-58}\) Using the structured Yosipovitch itch questionnaire, among 230 patients who returned a complete and detailed questionnaire, pruritus was referred to by 80% of the patients. In addition, the psoriasis area and severity index was significantly higher in patients with pruritus.\(^{55}\) The study of patients with moderate-to-severe plaque psoriasis showed that 96% of patients feel some itching, and among them, 62% reported severe itching. Further, the Dermatology Life Quality Index, Hospital Anxiety and Depression Screening Anxiety, Functional Assessment of Chronic Illness Therapy-Fatigue, Euro-Qol-5D VAS, and Medical Outcomes Study Sleep Index II significantly correlate with pruritus, indicating alteration of QOL in psoriasis patients by pruritus. In the epidermis of psoriasis patients with pruritus, the expression of \( \kappa \)-opioid receptor and dynorphin A was significantly decreased compared with in healthy controls.\(^{59}\) Therefore, a \( \kappa \)-opioid system in the psoriatic epidermis plays some role in the regulation of itching. According to these facts, nalfurafine can be effective in treating pruritus in psoriasis.

The injection of ethynylestradiol for 2 weeks reportedly induced cholestasis, and subsequently increased serum concentrations of bile acids and caused a higher incidence of body scratching compared with vehicle in rats, providing an animal model for scratching behavior secondary to cholestasis. Pretreating the rats with nalfurafine inhibited ethynylestradiol-induced scratching. Therefore, nalfurafine has the potential to reduce cholestatic pruritus.\(^{60}\) The aged MRL/lpr mice, a model of autoimmune disease, showed spontaneous scratching behavior. The frequency of this scratching behavior was not reduced by oral administration of an antihistamine chlorpheniramine, suggesting the behavior is antihistamine-resistant. In contrast, the oral administration of nalfurafine inhibited the scratching behavior without causing gross behavioral changes, suggesting nalfurafine may be beneficial in patients with autoimmune disease-associated pruritus.\(^{61}\)

Chloroquine, a chemotherapeutic drug for malaria fever, can cause generalized pruritus.\(^{62,63}\) Experimentally, scratching behavior was induced by chloroquine in mice. However, when the mice were pretreated with nalfurafine, scratching was strongly suppressed.\(^{64}\) Therefore, nalfurafine also is hopeful as a treatment for pruritus induced by drugs, including chloroquine.

In addition to the antipruritic activity, the analgesic effect of nalfurafine was examined using mice inoculated with herpes simplex virus I, and pain-related responses of the hind paw were monitored with von Frey filaments.\(^{65}\) Then it was found that oral nalfurafine suppressed herpetic and postherpetic pain dose-dependently. Thus, nalfurafine is also hopeful for antiherpetic and postherpetic neuralgia.

**Conclusion and perspective**

The newly approved oral drug nalfurafine hydrochloride (2.5 and 5 \( \mu \)g/day), a \( \kappa \)-opioid receptor agonist, has been proven to be safe and effective for the treatment of HD patients with uremic pruritus resistant to antihistamines. This drug suppresses itching and subsequently improves the mental condition of HD patients. Nalfurafine can be recommended as a hopeful option for pruritus in HD patients when conventional treatments are not effective. Because \( \kappa \)-opioid receptors are expressed in the epidermis, topical nalfurafine may be developed for the treatment of pruritus associated with renal failure, hepatic diseases, and other pruritic skin diseases in the future. Because skin eruptions were not assessed in a previous clinical trial,\(^{66}\) it should be interesting to investigate the effect of nalfurafine on exacerbations, lichen simplex, prurigo nodularis, and acquired perforating dermatosis possibly caused by uremic pruritus. From recent data showing \( \kappa \)-opioid receptor expression in
the epidermis of atopic dermatitis and psoriasis, nalfurafine hydrochloride will be potentially used for these two skin diseases. In addition, various animal experiments suggest this drug will be helpful as an antipruritic drug for a wide range of skin diseases. In the future, clinical study is expected to be planned for various recalcitrant types of pruritus other than uremic pruritus.

As a new antipruritic for uremic pruritus, gabapentin and pregabalin were reported to show a high efficacy ratio (81%). Moreover, pregabalin has been recently examined in a randomized double-blind study and found to reduce VAS for pruritus by 66 mm at 12 weeks after starting the drug. This reduction is remarkably larger than that by nalfurafine (41.6 mm at week 24 and 44 mm at week 52). Therefore, more new reagents for uremic pruritus can be expected to be developed in the near future.

Disclosure

The author reports no conflicts of interest in this work.

References